Related Experiment Video
Updated: Oct 14, 2025
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
Modulation of intrinsic inhibitory checkpoints using nano-carriers to unleash NK cell activity
Guy Biber1, Batel Sabag1, Anat Raiff1
1The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel.
Abstract:
Natural killer (NK) cells provide a powerful weapon mediating immune defense against viral infections, tumor growth, and metastatic spread. NK cells demonstrate great potential for cancer immunotherapy; they can rapidly and directly kill cancer cells in the absence of MHC-dependent antigen presentation and can initiate a robust immune response in the tumor microenvironment (TME). Nevertheless, current NK cell-based immunotherapies have several drawbacks, such as the requirement for ex vivo expansion of modified NK cells, and low transduction efficiency. Furthermore, to date, no clinical trial has demonstrated a significant benefit for NK-based therapies in patients with advanced solid tumors, mainly due to the suppressive TME. To overcome current obstacles in NK cell-based immunotherapies, we describe here a non-viral lipid nanoparticle-based delivery system that encapsulates small interfering RNAs (siRNAs) to gene silence the key intrinsic inhibitory NK cell molecules, SHP-1, Cbl-b, and c-Cbl. The nanoparticles (NPs) target NK cells in vivo, silence inhibitory checkpoint signaling molecules, and unleash NK cell activity to eliminate tumors. Thus, the novel NP-based system developed here may serve as a powerful tool for future NK cell-based therapeutic approaches.
Insights
This study introduces a novel nanoparticle system to enhance natural killer (NK) cell immunotherapy. The system silences inhibitory molecules in NK cells, boosting their tumor-killing potential for cancer treatment.
Area of Science:
- Immunology
- Nanotechnology
- Cancer Therapy
Background:
- Natural killer (NK) cells are crucial for immune defense against viruses and tumors.
- NK cells show promise in cancer immunotherapy due to their direct tumor cell killing ability.
- Current NK cell therapies face challenges like ex vivo expansion needs, low transduction efficiency, and the suppressive tumor microenvironment (TME).
Purpose of the Study:
- To develop a non-viral delivery system to overcome limitations in NK cell-based immunotherapies.
- To enhance NK cell activity against solid tumors by targeting inhibitory molecules.
Main Methods:
- A lipid nanoparticle (NP)-based delivery system was engineered to encapsulate small interfering RNAs (siRNAs).
- The NPs were designed to target NK cells in vivo.
- The encapsulated siRNAs were used to gene-silence key inhibitory NK cell molecules: SHP-1, Cbl-b, and c-Cbl.
Main Results:
- The NP system successfully targeted NK cells in vivo.
- Inhibitory checkpoint signaling molecules (SHP-1, Cbl-b, c-Cbl) were silenced in NK cells.
- NK cell activity was unleashed, leading to tumor elimination.
Conclusions:
- A novel NP-based delivery system offers a promising strategy for NK cell-based immunotherapy.
- This approach can overcome current obstacles and enhance NK cell efficacy in treating advanced solid tumors.
Related Concept Videos
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:28Cells of the Innate Immune Response
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...